hero section gradient
15 handpicked stocks

Can't Stop, Won't Stop Addictive Products

These companies have mastered the art of capturing your attention and keeping you scrolling, swiping, and streaming. Carefully selected by our analysts, this collection features platforms designed to be irresistible, turning user engagement into predictable revenue streams.

Author avatar

Han Tan | Market Analyst

Published on June 17

Your Basket's Financial Footprint

Concise interpretation of the basket's market capitalisation and investor takeaways, adhering to FCA guidelines.

Key Takeaways for Investors:
  • Large-cap dominance tends to mean lower volatility, more stable performance, and broader market-like returns.
  • Use as a core holding in diversified portfolios, not a speculative, high-growth trade.
  • Likely to deliver steady long-term value, not rapid short-term explosive gains.
Total Market Cap
  • META: $1.84T

  • ROKU: $14.36B

  • PLTK: $1.38B

  • Other

About This Group of Stocks

1

Our Expert Thinking

These companies have built platforms that keep users hooked through features like infinite scroll, personalized feeds, and habit-forming design. When users can't look away, companies can monetize that attention through ads, subscriptions, and in-app purchases, creating reliable revenue streams.

2

What You Need to Know

This collection spans social media giants, streaming services, gaming companies, and interactive platforms. What unites them is their ability to capture and maintain user attention, creating a powerful competitive advantage as more of our lives move online.

3

Why These Stocks

Each company was selected for its demonstrated ability to create digitally addictive experiences. Our analysts specifically looked for platforms with high engagement metrics and innovative features designed to maximize time spent and user retention.

Why You'll Want to Watch These Stocks

🧠

Designed to Be Addictive

These platforms aren't just popular by accident - they're engineered using behavioral psychology to keep users coming back. As engagement deepens, revenue opportunities multiply.

🤖

AI Is Making Them Even Stickier

Artificial intelligence is revolutionizing how these platforms personalize content, making them increasingly effective at holding user attention and potentially driving stronger future growth.

📱

The Attention Economy Is Booming

As digital screen time continues to increase globally, companies that excel at capturing and monetizing attention are positioned to benefit from this fundamental shift in how we spend our time.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions